Establishment and Use of Epidemiological Cutoff Values for Molds and Yeasts by Use of the Clinical and Laboratory Standards Institute M57 Standard
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Breakpoints are used to predict whether an antifungal agent will be clinically effective against a particular fungal isolate. They are based on a combination of MIC values, pharmacokinetic/pharmacodynamic values, and clinical outcome data. For many fungus-antifungal combinations, these data might never be available. For these combinations, epidemiological cutoff values (ECVs) provide a methodology for categorizing isolates as either wild type (WT) or non-WT. In this review, we define ECVs, explain how they are generated using the CLSI methodology in standard M57, and describe how they can be used in clinical practice.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Further effects could be due to tolerance or trailing, rather than resistance9,25–28 because the MIC was not altered at 24 h. Instead, increased growth in the presence of the drug (relative to a reference strain) was usually detected at 48 h.”
From Drug resistance and tolerance in fungi. (2020) · cites this paper as [25]
In the citing paper
“Inhibitors of heat shock protein 90 (Hsp90)82, calcineurin21,25,26, target of rapamycin (TOR)83 and mutants that affect Rim10184 (a transcription factor involved in the pH response pathway) effectively eliminate tolerance and greatly increase the fungicidal activity [G] of fluconazole across a diverse set of isolates with different tolerance levels (Fig. 1E; Box 5).”
From Drug resistance and tolerance in fungi. (2020) · cites this paper as [25]
Citations
Cites
Turnidge, J., Kahlmeter, G., & Kronvall, G. (2006) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2006.01377.x · Cited by 397 · cited 2×
“Finally, as mentioned above, the iterative method of ECV determination is used to generate the final ECV (4).”
MethodEuropean harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteria
Kahlmeter, G. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg312 · Cited by 397 · cited 1×
“The first method, the visual method, simply plots the distribution of MIC values, and a reviewer sets the ECV by sight, usually 1 to 2 dilutions beyond the modal MIC value but before the distribution endpoint, disregarding any tailing of the distribution (small numbers of MICs at the high end of the distribution) (2).”
MethodPfaller, M. A., Diekema, D. J., Andes, D., Arendrup, M. C., Brown, S. D., Lockhart, S. R., Motyl, M., & Perlin, D. S. (2011) · Drug Resistance Updates · doi:10.1016/j.drup.2011.01.004 · Cited by 334
Self-citationEspinel-Ingroff, A., Aller, A. I., Canton, E., Castañón-Olivares, L. R., Chowdhary, A., Cordoba, S., Cuenca-Estrella, M., Fothergill, A., Fuller, J., Govender, N., et al. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01115-12 · Cited by 251 · cited 1×
“The cryptic species (sensu lato) will not necessarily have the same wild-type MIC range or resistance profile as the parental species (sensu stricto), as was recently shown for the Cryptococcus neoformans and Cryptococcus gattii species complexes (6).”
BackgroundSelf-citationEspinel-Ingroff, A., Diekema, D. J., Fothergill, A., Johnson, E., Pelaez, T., Pfaller, M. A., Rinaldi, M. G., Canton, E., & Turnidge, J. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.00536-10 · Cited by 240
Pfaller, M. A., Espinel-Ingroff, A., Canton, E., Castanheira, M., Cuenca-Estrella, M., Diekema, D. J., Fothergill, A., Fuller, J., Ghannoum, M., Jones, R. N., et al. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.00248-12 · Cited by 174
Self-citationEspinel-Ingroff, A., Cuenca-Estrella, M., Fothergill, A., Fuller, J., Ghannoum, M., Johnson, E., Pelaez, T., Pfaller, M. A., & Turnidge, J. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00686-11 · Cited by 164
Self-citationEspinel-Ingroff, A., Colombo, A. L., Córdoba, S. B., Dufresne, P. J., Fuller, J., Ghannoum, M. A., González, G. M., Guarro, J., Kidd, S. E., Meis, J. F. G. M., et al. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02456-15 · Cited by 160
Self-citationWild-Type MIC Distributions and Epidemiological Cutoff Values for the Echinocandins and Candida spp
Pfaller, M. A., Boyken, L., Hollis, R. J., Kroeger, J., Messer, S. A., Tendolkar, S., Jones, R. N., Turnidge, J., & Diekema, D. J. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.01590-09 · Cited by 154
Pfaller, M. A., Diekema, D. J., Ghannoum, M. A., Rex, J. H., Alexander, B. D., Andes, D., Brown, S. D., Chaturvedi, V., Espinel-Ingroff, A., Fowler, C. L., et al. (2009) · Journal of Clinical Microbiology · doi:10.1128/jcm.00940-09 · Cited by 139
Self-citationEspinel-Ingroff, A. V., Chakrabarti, A., Chowdhary, A., Córdoba, S. B., Dannaoui, É., Dufresne, P. J., Fothergill, A. W., Ghannoum, M. A., González, G. M., Guarro, J., et al. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.04435-14 · Cited by 128
Self-citationEspinel-Ingroff, A., Pfaller, M. A., Bustamante, B., Canton, E., Fothergill, A., Fuller, J., Gonzalez, G. M., Lass-Flörl, C., Lockhart, S. R., Martin-Mazuelos, E., et al. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02615-13 · Cited by 105
Self-citationBerkow, E. L., Manigaba, K., Parker, J. E., Barker, K. S., Kelly, S. L., & Rogers, P. D. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01358-15 · Cited by 95
Espinel-Ingroff, A., Fothergill, A., Fuller, J., Johnson, E., Pelaez, T., & Turnidge, J. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01730-10 · Cited by 95
Pfaller, M. A., Castanheira, M., Diekema, D. J., Messer, S. A., & Jones, R. N. (2011) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2011.07.007 · Cited by 77
Espinel-Ingroff, A., Chowdhary, A., Gonzalez, G. M., Guinea, J., Hagen, F., Meis, J. F., Thompson, G. R., & Turnidge, J. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.04055-14 · Cited by 69
Espinel-Ingroff, A., Alvarez-Fernandez, M., Cantón, E., Carver, P. L., Chen, S. C.-A., Eschenauer, G., Getsinger, D. L., Gonzalez, G. M., Govender, N. P., Grancini, A., et al. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01250-15 · Cited by 67
Self-citationPfaller, M. A., Boyken, L., Hollis, R. J., Kroeger, J., Messer, S. A., Tendolkar, S., & Diekema, D. J. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.02161-10 · Cited by 61
Pfaller, M. A., Espinel-Ingroff, A., Bustamante, B., Canton, E., Diekema, D. J., Fothergill, A., Fuller, J., Gonzalez, G. M., Guarro, J., Lass-Flörl, C., et al. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02020-13 · Cited by 51
Self-citation
Research works printed but not linked: 2
- Clinical and Laboratory Standards Institute. 2016. Principles and procedures for the development of epidemiological cutoff values for antifungal susceptibility testing. CLSI supplement M57. Clinical and Laboratory Standards Institute, Wayne, PA.
- Clinical and Laboratory Standards Institute. 2016. Epidemiological cutoff values for antifungal susceptibility testing. CLSI supplement M59. Clinical and Laboratory Standards Institute, Wayne, PA.
Cited by
Drug resistance and tolerance in fungi.
Berman, J., & Krysan, D. J. (2020) · Nature Reviews Microbiology · doi:10.1038/s41579-019-0322-2 · Cited by 642
Antifungal Susceptibility Testing: Current Approaches
Berkow, E. L., Lockhart, S. R., & Ostrosky-Zeichner, L. (2020) · Clinical Microbiology Reviews · doi:10.1128/cmr.00069-19 · Cited by 368
“it is probable that it has developed resistance (167).”
BackgroundSelf-citationAlarming India‐wide phenomenon of antifungal resistance in dermatophytes: A multicentre study
Ebert, A., Monod, M., Salamin, K., Burmester, A., Uhrlaß, S., Wiegand, C., Hipler, U., Krüger, C., Koch, D., Wittig, F., et al. (2020) · Mycoses · doi:10.1111/myc.13091 · Cited by 280
Antimicrobial Susceptibility Testing of Antimicrobial Peptides to Better Predict Efficacy
Mercer, D. K., Torres, M. D. T., Duay, S. S., Lovie, E., Simpson, L., von Köckritz-Blickwede, M., de la Fuente-Nunez, C., O'Neil, D. A., & Angeles-Boza, A. M. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.00326 · Cited by 132
“Thus, an ECV is not a predictor of clinical success, but allows for prediction of whether an isolate has possible resistance to a given antimicrobial (Turnidge et al., 2006; Lockhart et al., 2017).”
BackgroundBeardsley, J., Halliday, C. L., Chen, S. C.-A., & Sorrell, T. C. (2018) · Future Microbiology · doi:10.2217/fmb-2018-0059 · Cited by 124
Metadata
- Authors
- Lockhart, S. R., Ghannoum, M. A., & Alexander, B. D.
- Affiliations
- Centers for Disease Control and Prevention (US)
- University Hospitals Cleveland Medical Center (US)
- Duke University (US)
- Venue
- Journal of Clinical Microbiology
- Publisher
- American Society for Microbiology
- Published
- 2017-05
- Volume
- 55
- Issue
- 5
- Pages
- 1262-1268
- ISSN
- 0095-1137 (ISSN-L)
- 1098-660X
- PMC
- PMC5405245
- OpenAlex
- W2587942285
- Cited by
- 81
- References
- 19
- Citations by year
- 2026: 10 · 2025: 8 · 2024: 9 · 2023: 10 · 2022: 6 · 2021: 7 · 2020: 13 · 2019: 11 · 2018: 4 · 2017: 3
- FWCI
- 6.53
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Journal of Clinical Microbiology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Oral HIV Research Alliance (BRS-ACURE-S-11-000049-110229)
- HHS | NIH | NIH Clinical Center (R01DE024228, RO1DE17846)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Microbiology (medical) › Bacterial Identification and Susceptibility Testing
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Keywords
- epidemiological cut-off values, molds, yeast, antifungal susceptibility breakpoints, antifungal agents, fungal isolates
- MeSH terms
- Antifungal Agents, Candidiasis, Cryptococcosis, Cryptococcus neoformans, Humans, Microbial Sensitivity Tests, Treatment Outcome, Drug Resistance, Fungal, Candida glabrata
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.